Presentazione di PowerPoint

1
Trial profile for the pharmacokinetics and
pharmacodynamics study in patients with
dyslipidaemia (A) and the ambulatory blood
pressure study (B)
Participants who received drug in period 1
received placebo in period 2 and vice versa
Rajesh Krishna, et al. Lancet 20073701907-14
2
Change from baseline versus time profiles for
serum HDL-C (A), LDL-C (B), apolipoprotein A-I
(C), and apolipoprotein B (D) after
administration of anacetrapib or placebo to
patients with dyslipidaemia
Rajesh Krishna, et al. Lancet 20073701907-14
3
Hourly mean systolic (A) and diastolic (B) blood
pressure (SE) over 24 h post-dose on day 10 after
administration of anacetrapib (or matching
placebo) in healthy middle-aged and elderly
people (N22)
R. Krishna, et al. Lancet 20073701907-14
4
Mean ambulatory systolic and diastolic blood
pressure at 24 h post-dose on day 10 after
administration of anacetrapib or placebo in
healthy middle-aged and elderly people (N22)
Rajesh Krishna, et al. Lancet 20073701907-14
5
Incidence of adverse events in patients with
dyslipidaemia
Rajesh Krishna, et al. Lancet 20073701907-14
6
Incidence of adverse events in ambulatory blood
pressure study
Rajesh Krishna, et al. Lancet 20073701907-14